Global research dynamics in urea cycle disorders: a bibliometric study highlighting key players and future directions. [PDF]
Wang Y, Wang X, Zhang H, Zhu B.
europepmc +1 more source
Identification of rare variants causing urea cycle disorders: A clinical, genetic, and biophysical study. [PDF]
Liu F +6 more
europepmc +1 more source
A novel neutrophil‐hitchhiking, rocket‐inspired nanoplatform is developed to cross the blood‐brain barrier for sequential, spatiotemporal drug delivery. By responsive surface transformation in the ischemic penumbra, it precisely targets mitochondria to suppress Drp1‐mediated fission.
He Bai +17 more
wiley +1 more source
Perspectives on long-term medical management of urea cycle disorders: insights from a survey of UK healthcare professionals. [PDF]
Stepien KM +5 more
europepmc +1 more source
Rhoifolin directly targets NMNAT1, thereby activating nicotinamide salvage pathway and promoting intracellular NAD+ biosynthesis. Elevated NAD+ levels enhance SIRT1 activity, leading to FOXO1 deacetylation and nuclear translocation. Nuclear FOXO1 subsequently binds to the IL‐22 promoter, upregulating IL‐22 transcription and potentiating ILC3 effector ...
Hongqiong Yang +12 more
wiley +1 more source
Novel Treatment Strategy for Patients With Urea Cycle Disorders: Pharmacological Chaperones Enhance Enzyme Stability and Activity in Patient-Derived Liver Disease Models. [PDF]
Ramosaj A +15 more
europepmc +1 more source
This work demonstrates a novel energy regulation strategy using the long‐lived S₁ state as a “kinetic capacitor” to achieve temporally decoupled integration of photoinduced deformation and multicolor fluorescence in naphthalimide‐functionalized carbon dots. This dual‐channel programmable shunting of excited‐state energy establishes a dynamic single‐use
Jianye Zhang +6 more
wiley +1 more source
Mapping challenges in the accessibility of treatment products for urea cycle disorders: A survey of European healthcare professionals. [PDF]
Stolwijk NN +6 more
europepmc +1 more source
An α‐helical peptide, TAB12, designed to mimic the TRIM28 binding interface, competitively disrupts the TRIM28‐BRD7 interaction, thereby blocking ubiquitin‐mediated degradation of the tumor suppressor BRD7. This stabilization unleashes potent anti‐tumor effects across multiple tumor types with a favorable safety profile, offering a feasible strategy ...
Qingqing Wei +10 more
wiley +1 more source
Understanding the Natural History and the Effects of Current Therapeutic Strategies on Urea Cycle Disorders: Insights from the UCD Spanish Registry. [PDF]
Martín-Hernández E +48 more
europepmc +1 more source

